Fourth quarter results 2007
- Acquisition of Vitaflo Scandinavia AB completed - building an international
pharmaceutical company
- Revenues of 19 million in Q4 and 32 million in FY 07
- Positive EBITDA of 3.6 million in Q4 and 1.5 million in FY 07 - first year
with positive EBITDA
- Pro forma revenues of 60.1 million and EBITDA of 5.4 million FY 07
- Glucomed launched in the Czech Republic, the Slovak Republic and Austria
- 2 new products added to the Vitaflo portfolio
- Vitaflo to market Glucomed in Sweden, Denmark, Norway and Finland
For further information, please contact:
Øyvind W. Brekke, CEO Navamedic ASA
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40
Mobile: +47 91 19 81 64
Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA
E-mail: bor@navamedic.com
Office: +47 67 11 25 44
Mobile: +47 91 34 70 21